NIH partners with 16 drug companies in hopes of accelerating Covid-19 treatments and vaccines
WASHINGTON — The National Institutes of Health on Friday announced it would launch a sweeping public-private partnership between federal researchers and 16 pharmaceutical companies, aimed at coordinating and accelerating the development of Covid-19 treatments and vaccines.
The partnership, to be known as Accelerating Covid-19 Therapeutic Interventions and Vaccines, or ACTIV, is meant to standardize research between the federally funded researchers and a broad array of drug companies, and prioritize research into drugs and vaccines that are having high near-term potential.
